Survival Analysis Using Primary and Surrogate Endpoints

نویسندگان

  • Timothy Morgan
  • Gary Koch
  • Ed Davis
  • Gary Rozier
چکیده

GAIL E. TUDOR. Survival Analysis Using Primary and Surrogate Endpoints. (Under the direction of TIMOTHY M. MORGAN) Current survival techniques do not provide a good method for handling clinical trials with a large percent of censored observations. Some methods that have been proposed to increase the power of analyses· include covariate adjustment, multivariate models, use of surrogate endpoints and the use of time dependent covariates. This research proposes using time dependent surrogates of survival as outcome variables, in. conjunction with observed survival time to improve the precision in comparing the relative effects of two treatments on the distribution of survival time, or in estimating the parameters in the survival model, where the outcome measure is time to a specified event. This is in contrast to the standard method which uses the marginal density of survival time, T, only, or the marginal density of the surrogate, X, only, therefore, ignoring some available information. The surrogate measure, X, may be a fixed value or a time dependent variable, X(t). X is a summary measure of some of the covariates measured throughout the trial that provide additional information on a subject's survival time. It is possible to model these time dependent covariate values and relate the parameters in the model to the parameters in the distribution of T given X. The efficiency of the standard method compared to the proposed method is presented for several different cases which use a fixed or time dependent variable. The last example applies data from a study on the effects of lipids on coronary heart disease. The proposed method is always as efficient or more efficient than the standard method. When the treatment effects survival by having a multiplicative effect on the conditional hazard the proposed method is most efficient when the values of X are very heterogeneous and there is little censoring. When treatment affects the distribution of the surrogate measure, X, only, the proposed method is most efficient when the values of X are homogeneous and there is a large amount of censoring. When both are affected the largest gain is achieved when X is very heterogeneous and there is little censoring.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints

We investigate the effect of the choice of parameterisation of meta-analytic models and related uncertainty on the validation of surrogate endpoints. Different meta-analytical approaches take into account different levels of uncertainty which may impact on the accuracy of the predictions of treatment effect on the target outcome from the treatment effect on a surrogate endpoint obtained from th...

متن کامل

Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trial

The gold standard endpoint in trials of locoregionally advanced nasopharyngeal carcinoma (NPC) is overall survival (OS). Using data from a phase III randomized trial, we evaluated whether progression-free survival (PFS), failure-free survival (FFS), distant failure-free survival (D-FFS) or locoregional failure-free survival (LR-FFS) could be reliable surrogate endpoints for OS. Between July 200...

متن کامل

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology

Overall survival (OS) is the gold standard in measuring the treatment effect of new drug therapies for cancer. However, practical factors may preclude the collection of unconfounded OS data, and surrogate endpoints are often used instead. Meta-analyses have been widely used for the validation of surrogate endpoints, specifically in oncology. This research reviewed published meta-analyses on the...

متن کامل

Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework.

OBJECTIVES To measure the relationship between randomized controlled trial (RCT) efficacy and real-world effectiveness for oncology treatments as well as how this relationship varies depending on an RCT's use of surrogate versus overall survival (OS) endpoints. METHODS We abstracted treatment efficacy measures from 21 phase III RCTs reporting OS and either progression-free survival or time to...

متن کامل

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials

Recent major phase III trials led to the approval of immune checkpoint inhibitors (ipilimumab, pembrolizumab, and nivolumab) in metastatic malignant melanoma (MM). We aim to assess whether median progression-free survival, and 1 and 2-year overall survival (OS) rates are reliable surrogate endpoints for median OS through a meta-analysis of published trials involving immunotherapy. A systematic ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 1991